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Abstract
Background: Juglone is a natural pigment, which has cytotoxic effect against various human tumor cells. However,
its cytotoxicity to glioma cells, especially to tumor stem-like cells (TSCs) has not been demonstrated.
Methods: TSCs of glioma were enriched from U87 and two primary cells (SHG62, and SHG66) using serum-free
medium supplemented with growth factors, including bFGF, EGF and B27. After treatment of juglone with gradient
concentrations (0, 10, 20, and 40 μM), the viability and apoptosis of TSCs were evaluated by WST-8 assay and flow
cytometry. Reactive oxygen species (ROS) was labeled by the cell-permeable fluorescent probe and detected with
flow cytometry. ROS scavenger (NAC) and p38-MAPK inhibitor (SB203580) were applied to resist the cytotoxic effect.
Caspase 9 cleavage and p38 phosphorylation (P-p38) were quantified by western blot. Juglone as well as
temozolomide (TMZ) were administrated in intracranial xenografts and MR scan was performed every week to
evaluate the anti-tumor effect in vivo.
Results: Juglone could obviously inhibit the proliferation of TSCs in glioma by decreasing cell viability (P < 0.01)
and inducing apoptosis (P < 0.01), which was accompanied by increased caspase 9 cleavage in a dose-dependent
manner (P < 0.01). In the meantime, juglone could generate ROS significantly and increase p38 phosphorylation
(P < 0.01). In addition, pretreatment with ROS scavenger or p38-MAPK inhibitor could reverse juglone-induced
cytotoxicity (P < 0.01). More importantly, juglone could also suppress tumor growth in vivo and improve the survival
of U87-bearing mice compared with control (P < 0.05), although TMZ seemed to have better effect.
Conclusions: Juglone could inhibit the growth of TSCs in gliomas through the activation of ROS-p38-MAPK
pathway in vitro, and the anti-glioma effect was validated in vivo, which offers a potential therapeutic agent to
gliomas.
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Background
As one of the most deadly primary brain tumors, glio-
blastoma (GBM) has the characteristics of rapid growth
and high invasiveness. The median survival time of GBM
has been prolonged to about 14.6 months even after
comprehensive treatments of surgery, chemotherapy and
radiotherapy [1]. After many endeavors, temozolomide
(TMZ) emerged as a feasible first-line chemotherapeutic
agent through DNA alkylation in glioma cells, which was
validated by phase III clinical trial [2, 3]. However, some
tumors without MGMT methylation have been reported
to be resistant to TMZ, and thus limiting its efficiency [4].
In the meantime, a subgroup of quiescent tumor stem-
like cells (TSC) have been demonstrated to re-initiate
tumor growth after TMZ treatment [5]. Bevacizumab
(anti-VEGFA), which could only benefit proneural
subtype of GBM [6], has also not been encouraging.
Therefore, it is necessary to find some novel chemo-
therapeutic agents targeting GBM.
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Natural products have recently received much atten-
tion as potential therapeutic agents, e.g., matrine as a
cell cycle blocker [7], camptothecin as a proliferation in-
hibitor [8], and podophyllotoxin as an apoptosis inducer
[9]. Similarly, juglone, a lipid-soluble drug, has been
widely used as a chemotherapeutic agent in Chinese
herbal medicine against various tumors, including leu-
kaemia [10], melanoma [11], gastric cancer [12] and pan-
creatic cancer [13] through the activation of apoptotic
caspase cascade and the increase of ROS (reactive oxygen
species) [14, 15]. Recently, juglone has been found to in-
hibit cell proliferation and to reduce the invasiveness of
C6 rat glioma cells in vitro [16]. However, if it could exert
a cytotoxic effect in vivo remains unknown.
TSCs in glioma could not be completely eliminated
even through combined treatment modality, and thus
become the main reason of chemotherapy resistance and
the root of tumor relapse [17]. Therefore, we explored
the anti-tumor effect of juglone to glioma TSCs and its
potential mechanism in this study. Furthermore, we also
compared its effect with TMZ in order to provide an
available alternative for patients after chemotherapeutic
treatment failure.
Methods
Glioma stem-like cells culture
U87 was purchased from American Type Culture Collection
(Manassas, VA). GBM primary cells (SHG62 and SHG66)
were established in our laboratory previously [18]. The
glioma TSCs were cultured in serum-free medium (DMEM/
F12) supplemented with growth factors, including 10 ng/mL
bFGF (basic Fibroblast Growth Factor), 20 ng/mL EGF
(Epidermal Growth Factor), and B-27 (1:50 dilution; Life
Technologies, Carlsbad). Cell cultures were maintained in a
5% CO2 humidified incubator at 37 °C.
Cell viability assays
Juglone (St Louis, MO) was dissolved in dimethyl sulfox-
ide (DMSO) and diluted in DMEM/F12. The final work-
ing concentration of DMSO was 100 mM. Cell viability
was measured by the WST-8 assay (Kumamoto, Japan)
following optimized manufacturer’s recommendation.
Briefly, cells were seeded at a density of 2 × 104cells/
200ul/well in 96-well plates, and then incubated over-
night in serum-free medium. The cells were pretreated
with and without NAC (a ROS scavenger, 2 mM), or
SB203580 (an inhibitor of p38-MAP kinase, 5 μM) for
1 h. Then the cells were treated with different concen-
trations of juglone (0, 10, 20, and 40 μM). After 48 h in-
cubation, 20 μl WST-8 was added to each well, and the
cells were incubated for another 6 h. The optical density
(OD) was detected at 450 nm with microplate spectro-
photometer (BD Biosciences, San Jose, CA). The per-
centage of viable cells was determined by the formula:
ratio (%) = [OD (juglone) - OD (blank)/OD (control)
-OD (blank)] × 100. The experiment were triplicated,
and each contained six replicates.
Cell apoptosis and death assay
For cell apoptosis assay, GBM cells in serum-free
medium were treated with juglone (0, 20, and 40 μM)
for 48 h, 1 × 105 cells were harvested and incubated in
100 μL labeling solution (5 μL of Annexin V FITC, 5 μL
of PI, 10 μL of 10 × binding buffer and 80 μL of H2O) in
darkness at room temperature for 15 min, after that,
400 μL of binding buffer was added to stop the staining
reaction. For cell death assay, the cells were pretreated
with or without NAC (Sigma Aldrich, 2 mM), or
SB203580 (Sigma Aldrich, 5 μM) for 1 h. Then the cells
were treated with juglone (0, 40 μM) for 48 h. Following
incubation, cells were collected and fixed in 70% ethanol
for 24 h at 4 °C. After that, the cells were resuspended
in 500 μL phosphate buffer solution (PBS) containing
RNaseA (10 mg/mL, 50 μL) and PI (2 mg/mL, 10 μL).
The mixture was incubated in the dark at 37 °C for
30 min. For cell apoptosis and death assay, cells were
then analyzed on a FACS Calibur cytometer (Becton
Dickinson, San Joe CA). The data were analyzed using
FlowJo software V6.0 (Tree star, Ashland OR). Early apop-
totic cells are defined as annexin V+/PI−, whereas late
apoptotic/necrotic cells are defined as annexin V+/PI+.
The extent of cell death was determined by evaluating the
sub G1 fraction. The experiments were triplicated.
Evaluation of ROS generation
ROS was labeled by the cell-permeable fluorescent probe
(2,,7,- Dichloro- fluorescein diacetate, DCFDA, Sigma
Aldrich) and detected with flow cytometry. Briefly, cells
were exposed to various concentrations of juglone (0,
20, and 40 μM) for 24 h and then loaded with DCFDA
(10 μM) in serum-free medium. Following incubation at
37 °C for 30 min, cells were washed with PBS and fluor-
escence was measured with flow cytometry. The mean
fluorescence intensity (MFI) data was analyzed by
FlowJo software. The MFI experiments were repeated
three times.
Western blot assay
Cells were treated with different concentrations of
juglone (0, 20, and 40 μM) for 48 h. Total protein ex-
tracts were obtained from lysis buffer (150 mM NaCL,
1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and
50 mM Tris-Cl pH 8.0, 2 ug/mL aprotinin, 2 ug/mL leu-
peptin, 40 mg/mL of phenylmethylsulfonyl fluoride,
2 mM DTT). The protein concentration was determined
by the Bradford assay (BioRad, Hercules, CA), and sam-
ples were separated on SDS-PAGE, and then transferred
onto polyvinylidene difluoride (PVDF) membranes. The
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membranes were immunoblotted with primary Abs
against cleaved caspase 9 (Cell Signaling Technology,
1:1000), P-p38 (Cell Signaling Technology,1:1000), and
β-actin (Cell Signaling Technology,1:10000) overnight at
4 °C, followed by horseradish peroxidase (HRP) conju-
gated secondary Ab (BioRad,1:3000). Detection was
carried out using Supersignal West Femto Chemilumin-
escent Substrate (Pierce, Rockford, IL). β-actin was taken
as reference and the band intensities were quantified
using UN-SCAN-IT gel analysis software (Silk Scientific,
Orem, UT).
Cytotoxicity of juglone on glioma stem-like cells in vivo
Female BALB/c-nu mice (8–10 week) were obtained from
SlacLaboratoryAnimal Company (Shanghai, China). Ani-
mal experiment was conducted according to protocols
approved by the Institutional Animal Care and Use Com-
mittee at Fudan University. Animals were housed with a
12 h light/dark cycle, and acclimated to their environment
as least 1 week prior to experimentation. Micewere anes-
thetized intraperitoneally with 10% chloral hydrate and
stereotactically inoculated with 1 × 105 U87 stem-like cells
in 10uL PBS via micro-syringe into the right forebrain
(2.5 mm lateral and 1 mm anterior to bregma, at a 3 mm
depth from the skull surface). 3 days after the inoculation,
the mice were randomly distributed into three groups, in-
cluding vehicle control group, juglone treatment group,
and TMZ treatment group. The number of animals in each
group was 8. Juglone or TMZ was dissolved in DMSO and
diluted in PBS; the final concentration of DMSO was
20 mg/ml [19]. PBS containing the same concentration of
DMSO was used as vehicle control. Juglone treatment
group was injected intraperitoneally with juglone
(1 mg/kg) every 3 days, while TMZ treatment group
was injected intraperitoneally with TMZ (25 mg/kg)
every day. The total drug injections were 5 times per
animal. The mice were monitored every three days,and
the tumor were evaluated weekly using enhanced MR scan
(1.5 T, gadolinium,Bayer Schering Pharma AG,0.2 ml/kg).
Statistics
All data were presented as the mean ± standard deviation
(SD). Data analysis was performed by one-way analysis of
variance (ANOVA). For comparison of two groups, a stu-
dent’s t-test was used. Differences with P values < 0.05
were considered to be statistically significant.
Results
Juglone is cytotoxic to glioma stem-like cells
The stem-like cell viability of U87, SHG62 and SHG66
were evaluated by WST-8 assay after treatment with
juglone for 48 h. As shown in Fig. 1b, juglone (10, 20,
40 μM) could dramatically decrease the viability of gli-
oma stem-like cells as compared to the control (P < 0.01),
and the cell viability fell significantly to 65.3 ± 5.06% and
40.7 ± 8.21% after treated with higher concentration of
juglone. Meanwhile, stem-like cell spheres formation
decreased gradually after juglone treatment in a dose-
dependent manner, accompanied with cell shrinkage, re-
duction of cell adherence (Fig. 1c).
Juglone could induce glioma stem-like cells apoptosis
To determine if juglone could induce apoptosis, the per-
centage of Annexin V+PI− and Annexin V−PI+ U87 stem-
like cells after concentration gradients (0, 20, and 40 μM)
were measured with flow cytometry. As shown in Fig. 2a
Fig. 1 Juglone could decrease cell viabilityof glioma stem- like cells in vitro. a Chemical structure of juglone. b Cell viability (U87, SHG62 and
SHG66) decreased obviously after treatment with juglone at various concentrations (10, 20, and 40 μM) as compared to control (**P < 0.01). c The
cell morphology (100×) of juglone-treated U87 showed that stem-like cell spheres formation decreased gradually after juglone treatment in a
dose-dependent manner
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and b, juglone (20 μM) increased percentage of Annexin
V+PI−and Annexin V−PI+cells by 49.1 ± 9.15% and 11.1 ±
7.15% as compared to control (P < 0.01). However, juglone
(40 μM) increased the percentage of Annexin V+PI− and
Annexin V−PI+ cells by 12.1 ± 7.35% and 51.1 ± 8.52% as
compared to control (P < 0.01). In the meantime, juglone
could increase caspase 9 cleavage (Fig. 2c and d), which
indicated juglone-induced apoptosis.
Juglone could generate ROS and activate p38-MAPK
pathway
Juglone-induced ROS generation was obvious in a
dose-dependent manneras compared to vehicle control
(P < 0.01) (Fig. 3a and b). As demonstrated by western
blot (Fig. 3c and d), juglone (20, 40 μM) treatment signifi-
cantly increased p38 phosphorylation (P < 0.01),which
indicated p38-MAPK pathway activation in TSCs.
Fig. 2 Juglone could induce apoptosis of glioma stem-like cells. a FACS analysis indicated that juglone could significantly induce apoptosis at
different concentrations. b Statistic analysis indicated that juglone could significantly induce both early apoptosis and late apoptosis as compared
to the control. c Juglone increased caspase 9 cleavage. d Quantification of caspase 9 cleavage with western blot (**P < 0.01)
Fig. 3 Juglone could generate ROS and activate p38 phosphorylation. a Flow cytometry showed that juglone-induced ROS generation was
increased in a dose-dependent manner. b Statistical data of ROS MFI in different groups (**P < 0.01). c Juglone treatment significantly increased
p38 phosphorylation in a dose-dependent manner. d Statistical data of P-p38 protein at different concentrations using western blot (**P < 0.01)
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NAC and SB203580 pretreatment could reverse juglone-
induced growth inhibition of glioma stem-like cells
As demonstrated by WST-8 assay (Fig. 4a), juglone
(40 μM) treatment could decreased cell viability by
65 ± 2.53% (P < 0.01), whereas NAC and SB203580
could reversed the cytotoxic effect of juglone by 75 ±
3.18% (P < 0.01) and 58 ± 3.92%(P < 0.01). Cell death
data (Fig. 4b and c) showed that treatment with juglone
(40 μM) increased cell death by 17 ± 3.87% (P < 0.01),
while NAC and SB203580 pretreatment could reverse
juglone-mediated increases of cell death by 12.4 ± 2.33%
(P < 0.01) and 7.1 ± 2.91% (P < 0.01). All those results indi-
cated that ROS-p38-MAPK pathway was involved in the
juglone-induced cytotoxicity.
Juglone could reduce glioma growth in vivo and improve
the survival of glioma-bearing mice
Brain tumor models were successfully established, and
the anti-glioma effect of juglone in vivo was investigated.
Both juglone and TMZ could markedly retard glioma
growth in vivo confirmed by the MR scan results
(Fig. 5a). In the meantime, juglone and TMZ could both
significantly increase the survival time of glioma-bearing
mice as compared to control (P = 0.025, P = 0.017, re-
spectively. Figure 5b) and juglone could increase the
survival time by about 23.6%. Obviously, TMZ had a
better cytotoxic effect than juglone in vivo. All these re-
sults demonstrated that juglone could be an effective
anti-glioma agent.
Discussion
Since TSCs are responsible for resistance to chemother-
apy [5], novel therapeutic strategies targeting specifically
to TSCs are urgently needed. Spectrum Collection
Library (MicroSource, Gaylordsville, CT) was designed
to screen small compounds for anti-tumor chemothera-
peutic agents, and obtusaquinone (one natural product)
was identified to have pro-apoptotic effect on TSCs in
vitro and to suppress tumor in vivo [20]. However, the
suppression ratio was not as high as expected, and many
new promising agents needed confirmation by clinical
Fig. 4 Pretreatment with NAC and SB203580 could reverse juglone-
induced inhibition of glioma stem-like cells. a Statistic analysis
indicated that NAC or SB203580 could resist juglone-induced cell
viability decrease (**P < 0.01). b Statistic analysis indicated that NAC
or SB203580 could resist juglone-induced cell death (**P < 0.01).
c Flow cytometry showed that NAC or SB203580 pretreatment could
reverse the decrease of cell viability and the increase of cell death
induced by juglone (**P < 0.01)
Fig. 5 Juglone could retard glioma growth in vivo and prolong the
survival time of glioma-bearing mice. a MR images showed that
juglone group (1 mg/kg), as TMZ group (25 mg/kg) (P = 0.017),could
also retarded glioma growth in vivo comparing with control group
(P = 0.025). b Juglone treatment could improve, though less
significant than TMZ, the survival status of glioma-bearing miceas
compared with control (P < 0.05)
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studies. Here, we reported a natural pigment-juglone, a
lipid-soluble drug, which could easily pass the blood
brain barrier and exert anti-tumor effect against GBM
cells, especially against TSCs in vitro and in vivo.
In current study, juglone treatment could inhibit TSCs
growth by inducing apoptosis. We also observed that
juglone treatment could increase caspase 9 cleavage which
was consistent with previous study [14]. Juglone treatment
could induce apoptosis of glioma cells at both early and late
stage. These results indicated that juglone could exert dif-
ferent biological function under different concentrations.
Many possible mechanisms have been reported to be
involved in the juglone-induced anti-tumor effect,
among which ROS-based pathways were investiagted the
most [10, 12]. Tumor cells presented higher level of
ROS than normal cells [21]. In addition, high ROS con-
centration could induce cell apoptosis and necrosis in
relation with the severity and the duration of exposure
[22]. Therefore, many ROS-inducing agents are cur-
rently used in clinical trials for different tumors [21, 23].
These agents could not only act as direct inhibitors of
cancers, but also sensitize tumor cells to chemotherapies
[24]. In this study, we evaluated the growth inhibition
and apoptosis induction by juglone in human GBM
TSCs in vitro and in vivo, and we also confirmed that
ROS was involved in juglone-induced apoptosis. These
findings were further supported by the pretreatment
with NAC, which could block the cytotoxicity of juglone
as a ROS scavenger. Previous studies indicated that ROS
could induce the activation of the p38-MAPK pathway,
which is involved with apoptosis [25, 26]. In this study,
we also found that juglone could activate the p38-
MAPK pathway via ROS generation, and pretreatment
with SB203580 could reverse the ROS-induced effect. Be-
sides p38-MAPK pathway, many other pathways could be
activated by ROS, such as ROS-AMPK-mTOR pathway
and ROS-ERK/AKT-p53 pathway [27, 28], which need to
be validated in gliomas. Juglone could also exert cytotoxic
effect as a Pin-1 (Peptidyl-prolyl cis/trans isomerase 1) in-
hibitor through caspase cascade in nasopharyngeal carcin-
oma [29], which need further research. Therefore, juglone
might inhibit TSCs through multiple mechanisms.
There were also some limitations in this study. Juglone
could exert better anti-glioma effect than TMZ in vitro
(data not shown). However, the cytotoxic effect of juglone
was poorer than that of TMZ in vivo, which is partially
due to the various anti-tumor mechanisms. In the mean-
time, the dosage of juglone was low (1 mg/kg) in animal
experiment due to the consideration of the side effects.
So, we can modify specific chemical groups to reduce its
side effects while maintaining its cytotoxicity. The elabor-
ation of anti-tumor mechanism by juglone and better un-
derstanding of TSCs would also contribute to the future
treatment of gliomas. At least, juglone could offer us
another alternative for GBM patients with TMZ resistance
or failure, which needs further clinical investigation.
Conclusions
Juglone could inhibit proliferation and induce apoptosis
of glioma stem-like cells in vitro and in vivo, which was
mediated through the activation of ROS-p38- MAPK
pathway. So, juglone might serve as a potential chemo-
therapeutic agent for gliomas.
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